L-carnitine in patients with MS

Evaluating the effect of L-carnitine supplement on fatigue severity in patients with multiple sclerosis

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20211031052928N1

Enrollment

112

Registered

2021-12-13

Start date

2021-12-22

Completion date

Unknown

Last updated

2023-02-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fatigue in patients with Relapsing-remitting MS. Multiple sclerosis

Interventions

Intervention 1: Intervention group: Receiving 2 L-carnitine tabletes (1000 mg tablets made by Karen pharma food and supplements) daily for a period of 2 months. Intervention 2: Control group:receiving

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Patients with RRMS FSS>4 or MFIS>38 EDSS=3.5

Exclusion criteria

Exclusion criteria: EDSS=4 Depression Hypothyroidism Patients receiving medicines like Antipsychotics, MAOi, Benzodiazepines, TCAs, Anti-seizures and Barbiturates Severe kidney disfunction with GFR<30 ml/min

Design outcomes

Primary

Measure	Time frame
Fatigue. Timepoint: fatigue will be evaluated based on MFIS and FSS score before intervention and 2 months after. Method of measurement: Fatigue severity scale (FSS) and Modified fatigue impact scale (MFIS) Questionnaires.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSana Savadi Osgouei

Tabriz University of Medical Sciences

sanasavadi99@gmail.com+98 41 3327 6010

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026